LAVA Therapeutics (LVTX)

LAVA Therapeutics (LVTX) Stock Price & Analysis


LVTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.60 - $7.38
Previous Close$1.66
Average Volume (3M)60.58K
Market Cap
Enterprise Value-$45.27M
Total Cash (Recent Filing)$92.72M
Total Debt (Recent Filing)$4.63M
Price to Earnings (P/E)N/A
Mar 23, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
Shares Outstanding26,289,087
10 Day Avg. Volume88,600
30 Day Avg. Volume60,577
Standard Deviation0.26
Financial Highlights & Ratios
Price to Book (P/B)0.66
Price to Sales (P/S)3.66
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.58
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.54
Price Target Upside545.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was LAVA Therapeutics’s price range in the past 12 months?
LAVA Therapeutics lowest stock price was $1.60 and its highest was $7.38 in the past 12 months.
    What is LAVA Therapeutics’s market cap?
    Currently, no data Available
    When is LAVA Therapeutics’s upcoming earnings report date?
    LAVA Therapeutics’s upcoming earnings report date is Mar 23, 2023 which is in 2 days.
      How were LAVA Therapeutics’s earnings last quarter?
      LAVA Therapeutics released its earnings results on Nov 16, 2022. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.532 by $0.572.
        Is LAVA Therapeutics overvalued?
        According to Wall Street analysts LAVA Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does LAVA Therapeutics pay dividends?
          LAVA Therapeutics does not currently pay dividends.
          What is LAVA Therapeutics’s EPS estimate?
          LAVA Therapeutics’s EPS estimate is -$0.6.
            How many shares outstanding does LAVA Therapeutics have?
            LAVA Therapeutics has 25,797,735 shares outstanding.
              What happened to LAVA Therapeutics’s price movement after its last earnings report?
              LAVA Therapeutics reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.532. Following the earnings report the stock price went up 3.333%.
                Which hedge fund is a major shareholder of LAVA Therapeutics?
                Among the largest hedge funds holding LAVA Therapeutics’s share is Falcon Edge Capital, LP. It holds LAVA Therapeutics’s shares valued at 418K.


                  LAVA Therapeutics Stock Smart Score

                  The LAVA Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  LAVA Therapeutics

                  LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis